Published works

Toxicology

Toxicology

  • R29Biomarkers of drug-induced kidney toxicity.Ther Drug Monit.2018PubMed
  • R27The ischemic/nephrotoxic Acute Kidney Injury and the use of renal biomarkers in clinical practice.Eur J Intern Med.2016PubMed
  • R26The potential use of biomarkers in predicting contrast-induced acute kidney injury.Int J Nephrol Renovasc Dis.2016PubMed
  • 106Renoprotective effect of the xanthine oxidoreductase inhibitor, Topiroxostat,on Adenine-Induced Renal Injury.Am J Physiol Renal Physiol.310(11):F1366-1376, 2016.PubMed
  • 90Response of urinary liver-type fatty acid-binding protein to contrast media administration has a potential to predict one-year renal outcome in patients with ischemic heart disease.Heart Vessels.30(3): 296-303, 2015.PubMed
  • 79Human liver-type fatty acid-binding protein protects against tubulointerstitial injury in aldosterone-induced renal injury.Am J Physiol Renal Physiol.308(2): F114-121, 2014.PubMed
  • 70Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.AIDS Res Hum Retroviruses.30(4): 363-369, 2014.PubMed
  • 64Remote Ischemic Pre-Conditioning Alleviates ContrastInduced Acute Kidney Injury in Patients With Moderate Chronic Kidney Disease.Circulation Journal.77(12): 3037-3044, 2013.PubMed
  • 57Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury.Eur J Clin Invest.42(5): 557-563, 2012.PubMed
  • 47Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity.Am J Pathol.178(3): 1021-1032, 2011.PubMed
  • 36Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage.Am J Pathol.174(6): 2096-2106, 2009.PubMed
  • 32Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury.Am J Pathol.174(4): 1154-1159, 2009.PubMed
  • 28Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury.Nephron Exp Nephrol.108(1): e19-26, 2008.PubMed
  • 26Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury.Kidney Int.73(12): 1374-1384, 2008.PubMed
  • 23L-Type Fatty Acid Binding Protein Transgenic Mouse as a Novel Tool to Explore Cytotoxicity to Renal Proximal Tubules.Drug Metab. Pharmacokinet.23(4): 271-278, 2008.PubMed
  • 18A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure.Kidney Int.72(3): 348-358, 2007.PubMed
  • 17Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.Am J Kidney Dis.47(3): 439-444, 2006.PubMed

Category

Download product leaflet

For nonclinical safety evaluation

Urinary L-FABP kits for Rat, Dog, Cat, Monkey and Pig are available for the purpose of monitoring drug nephrotoxicity and drug effectiveness.
Top ▲ Home ▶